Hanmi Pharmaceutical has signed an exclusive supply and licensing agreement with Viet-Phap, a leading Vietnamese pharmaceutical firm, to export several of Hanmi’s hypertension combination drugs to the Vietnamese market, the company announced on November 5.
The agreement was signed at CPHI Worldwide 2025 in Frankfurt, held Oct. 28–30, where Hanmi CEO Park Jae-hyun and Viet-Phap CEO Nguyen Chi Dung attended the contract ceremony and affixed their signatures. Under the deal, Hanmi will supply finished combination hypertension products to Viet-Phap, which will handle regulatory approval, distribution and sales throughout Vietnam. The two companies will closely cooperate to ensure the successful market entry of Hanmi’s key drugs in Vietnam.
Viet-Phap, headquartered in Hanoi, is a private pharmaceutical company with more than 20 years of R&D experience and is regarded as one of Vietnam’s leading drugmakers. Since its founding in 2002, the company has imported and supplied a range of original and orphan drugs across multiple therapeutic areas.
Vietnam’s hypertension market is growing steadily, serving roughly 15 million patients and generating about $40 million annually. Leveraging its extensive local experience and expertise, Viet-Phap is expected to play a central role in establishing Hanmi’s flagship hypertension combination lineup in the market.
Through the partnership, both firms aim to expand access to hypertension treatments in Vietnam and address unmet medical needs to improve patient care. Nguyen Chi Dung said the collaboration would accelerate Viet-Phap’s growth and contribute to national health, and expressed interest in introducing additional products addressing other unmet medical needs. He added that combining Hanmi’s technology with Viet-Phap’s local expertise will enable Vietnamese clinicians and patients to access innovative therapies soon.
Hanmi CEO Park Jae-hyun said the agreement lays a foundation for Hanmi’s representative hypertension combination drugs to secure a stable foothold in Vietnam, and pledged continued support and cooperation to make effective treatments more accessible to local patients.
